Regenerative Medical Technology Group Inc. (RMTG)
OTCMKTS · Delayed Price · Currency is USD
0.0376
-0.0023 (-5.76%)
At close: Oct 19, 2026
RMTG Revenue
Regenerative Medical Technology Group had revenue of $4.02M in the quarter ending June 30, 2026, with 309.10% growth. This brings the company's total for the last twelve months to $9.41M, up 94.32% year-over-year. In the year 2025, Regenerative Medical Technology Group had annual revenue of $5.10M with 24.17% growth. That makes Regenerative Medical Technology Group the 37,611th largest company in the world by revenue and 4,945th in the United States.
Revenue (ttm)
9.41M
Revenue Growth
+94.32%
P/S Ratio
0.06
Revenue / Employee
9.41M
Employees
1
Market Cap
598.36K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10M | 992.82K | 24.17% |
| Dec 31, 2024 | 4.11M | 1.70M | 70.44% |
| Dec 31, 2023 | 2.41M | 879.73K | 57.49% |
| Dec 31, 2022 | 1.53M | 1.09M | 249.46% |
| Dec 31, 2021 | 437.89K | 382.81K | 694.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 18.05M |
| SQZ Biotechnologies Company | 12.12M |
| Helix BioMedix | 2.07M |
| Orgenesis | 1.04M |
| Halberd | 6.94K |
Regenerative Medical Technology Group News
- 1 day ago - RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign - Accesswire
- 13 days ago - RMTG's ISSCA Division Expands Global Online Academy With Ten New Curriculum Tracks - Accesswire
- 16 days ago - RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies - Accesswire
- 20 days ago - RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides - Accesswire
- 4 weeks ago - RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico - Accesswire
- 4 weeks ago - RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy - Accesswire
- 5 weeks ago - Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model - Accesswire
- 6 weeks ago - RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements - Accesswire